Search the Newsreel

Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery

Bristol-Myers Squibb (BMS) has partnered with Nvidia to establish a dedicated AI supercomputer for drug discovery, leveraging Nvidia's DGX SuperPOD technology. This "AI Center of Excellence" has been operational since March 2024, focusing on oncology research and predicting patient outcomes in immuno-oncology, and has …

Bristol Myers buys Nvidia's latest AI computing system for drug research

Bristol Myers Squibb announced its acquisition of Nvidia's cutting-edge DGX SuperPOD computing system, based on its new Vera Rubin architecture, to enhance AI-driven drug discovery and development. The pharmaceutical company aims to accelerate the identification of drug targets and improve success rates in clinical …

Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin

Bristol Myers Squibb (BMS) is significantly expanding its AI capabilities by deploying a second NVIDIA DGX SuperPOD, specifically built on eight DGX Vera Rubin NVL72 systems, to create the life science industry's most advanced AI factory. This initiative aims to democratize AI access for …

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital are establishing a new biopharmaceutical company focused on developing therapies for autoimmune diseases. The venture will be launched with $300 million in financing, primarily led by Bain Capital and including funds from the Canada Pension Plan Investment Board. …

Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma

Bristol Myers Squibb's stock (BMY) rose 5.5% after the FDA accepted its New Drug Application for mezigdomide in combination therapy for relapsed or refractory multiple myeloma, supported by positive Phase 3 data. This development is crucial for BMS as it aims to strengthen its …

Bristol-Myers Squibb Company (BMY) Q2 2024 earnings summary

Bristol-Myers Squibb (BMY) reported strong Q2 2024 results with revenues up 9% to $12.2B, driven by its Growth Portfolio, despite Revlimid declines. The company achieved several regulatory approvals and completed major acquisitions, expanding its pipeline. BMY also launched a $1.5B cost-saving initiative and raised …

Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Bristol-Myers Squibb (BMY) aims for sustained top-tier growth by focusing on transformational medicines, operational excellence, and disciplined capital allocation, having achieved double-digit revenue growth in 2024. The company highlights five key growth products and anticipates next-wave assets like the CELMoD platform and Milvexian to …

Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run?

Bristol-Myers Squibb (BMY) has seen a 31.9% return in the past year, leading to a mixed valuation picture. While the stock screens as undervalued on some market-based checks, with a fair P/E ratio of 19.2x compared to its current 17.0x, concerns about patent expirations …

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Bristol Myers Squibb Co. (BMY) stock advanced 3.05% to $60.51 on Thursday, outperforming the broader market which saw the S&P 500 Index fall 0.51% and the Dow Jones Industrial Average fall 0.20%. This marks the stock's second consecutive day of gains despite an overall …

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled

Bristol-Myers Squibb Co (BMY) stock rose 3.12% on July 15, driven by positive late-stage clinical trial results, increased institutional inflows into the defensive pharmaceutical sector, and favorable technical indicators. Despite facing patent expirations and pricing negotiation risks, the company's diversification strategy and pipeline successes …

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb (BMY), a biopharmaceutical company within the Zacks Medical - Biomedical and Genetics industry, has a strong track record of surpassing earnings estimates in its last two reports, with an average surprise of 9.64%. With recent estimates moving higher and a positive …

Bloomsbury expects record annual profit after strong start to the financial year (BMY)

Here's Why We Think Bloomsbury Publishing (LON:BMY) Might Deserve Your Attention Today

Bloomsbury’s new releases set to drive sales

Bloomsbury Publishing H2 Earnings Call Highlights

What Bloomsbury Publishing Plc's (LON:BMY) P/E Is Not Telling You

Bloomsbury lifts full-year outlook after AI licensing deal

Bloomsbury Publishing shares rise 4% after update; broker repeats 815p price target

Bloomsbury Publishing price target raised by leading investment bank - here's why

Three Quick Facts: Pets at Home, Bloomsbury Publishing and Wizz Air

Bloomsbury Publishing plc Ord 1.25p Shares share price | BMY

Bloomsbury Publishing Plc (BMY.L) Stock Price, News, Quote & History